WHEL-C-071 · Strong evidence · 8/10

aromatase inhibitors for endometriosis

A systematic review (including three RCTs) found that aromatase inhibitors combined with progestogens or oral contraceptives reduce endometriosis-related pain severity and improve quality of life.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Aromatase inhibitors suppress local and systemic estrogen production, reducing estrogen-dependent endometriotic lesion activity and associated pain.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 8 of 10 overall, a strong reading, from a direct rated strong in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline8.0 / 10 · Strong

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

All claims derive from a single systematic review ('Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review'). A single synthesis scores 1; the seven studies and three RCTs pooled inside it do not count as independent sources.

1 / 2

Rigor

The evidence is a systematic review encompassing multiple studies, including three RCTs of post-operative therapy. Systematic reviews and RCTs are the highest design tier, justifying a score of 2.

2 / 2

Specificity

Both the intervention (aromatase inhibitors) and the condition (endometriosis-related pain) are named directly and repeatedly in the claims and source title.

2 / 2

Plausibility

The claims assert efficacy in reducing pain but do not articulate the aromatase/estrogen-suppression mechanism. A plausible mechanism exists for endometriosis but is not spelled out in the quotes, so a score of 1 is appropriate.

1 / 2

Consistency

Multiple claims from the review consistently point in the same direction: AIs (combined with progestogens or OCPs) reduce pain severity and improve quality of life. The review synthesizes seven studies and three RCTs with concordant positive findings.

2 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1AIs combined with either progestogens or oral contraceptive pill reduce the severity of pain symptoms PubMed · PMID 21693038 ↗
2AIs combined with either progestogens or oral contraceptive pill reduce the severity of pain symptoms and improve quality of life PubMed · PMID 21693038 ↗
3Seven studies examined the efficacy of AIs in improving endometriosis-related pain symptoms PubMed · PMID 21693038 ↗
4three RCTs investigated the use of AIs as post-operative therapy in preventing the recurrence of pain symptoms after surgery for endometriosis PubMed · PMID 21693038 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index